Business Wire

Adtran wins two FTTH Innovation Awards for 50G PON and deep PON fiber monitoring

27.3.2025 17:00:00 EET | Business Wire | Press release

Share

Adtran today announced that it has won two FTTH Innovation Awards at the FTTH Conference 2025, recognizing its SDX 6405 optical line terminal (OLT) and ALM fiber monitoring platform as standout technologies supporting next-generation fiber networks. Organized by the FTTH Council Europe, the annual awards highlight innovations that accelerate fiber broadband rollouts while improving scalability, operational efficiency and user experience. Adtran received awards in two categories: ‘Active infrastructure – central network’ and ‘Installation equipment, tools, test & measurement instruments.’

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250326874284/en/

Adtran’s SDX 6405 OLT and ALM fiber monitoring platform received Innovation Awards at the FTTH Conference 2025.

“We’re honored to receive this recognition at the FTTH Conference. It’s a fantastic achievement for our team and a validation of the vision that’s guided our work: to help service providers build fiber networks that are open, scalable and ready for what comes next,” said Christoph Glingener, CTO of Adtran. “These wins reflect the dedication and expertise across our organization – from engineering to product to field support – and the close partnerships we’ve built with customers to solve real deployment challenges. Whether it’s enabling a future-proof transition to 50G PON or delivering affordable, real-time visibility into the access network, we’re focused on giving operators the tools to grow efficiently, improve reliability and stay ahead of demand.”

Adtran’s SDX 6405 won in the central network category for its 50G PON capabilities and disaggregated architecture. Part of the SDX 6000 Series, it supports GPON, XGS-PON and 50G PON on every port, enabling providers to deliver multigigabit services for residential, business and backhaul use cases – all over a single fiber. Its modular design eliminates the trade-off between near-term cost and long-term scalability. With the SDX 6405, providers can gradually add 50G OLTs to meet growing demand without disrupting existing subscribers or overhauling infrastructure. Built on an open, software-defined architecture, it integrates seamlessly into multivendor networks and supports automated service delivery through Adtran’s Mosaic Cloud Platform.

In the tools and measurement category, Adtran’s ALM was recognized for redefining how service providers monitor and manage fiber infrastructure. The compact, low-power device offers real-time, in-service visibility across the entire optical plant – enabling operators to detect and pinpoint issues before they affect customers. A key innovation is its deep PON assurance capability, which makes it possible to monitor fiber behind splitters without the need for demarcation reflectors. This is especially valuable for FTTH deployments, where scale and complexity can make fault detection and resolution a significant operational challenge. With support for fixed and mobile access networks, ALM empowers operators to increase service quality while lowering operational costs.

“These two awards recognize technologies that are solving critical challenges in access networks – from scaling bandwidth to ensuring new levels of service reliability,” commented Robert Conger, GM of software platforms and strategy at Adtran. “With 50G PON, we’re enabling a new generation of services that demand ultra-fast, highly reliable connectivity – whether that’s AI workloads, immersive experiences or industrial automation. At the same time, it delivers lower-speed services like 1G and 10G far more efficiently, helping operators simplify their access infrastructure and maximize return on investment. And with deep PON assurance, we’re giving operators the visibility they need to maintain those services at scale. It’s about building the foundation for sustainable, high-performance broadband that can evolve with demand.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250326874284/en/

Contacts

Published by
ADTRAN Holdings, Inc.
www.adtran.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.adtran.com
%2F&esheet=54229333&newsitemid=20250326874284&lan=en-US&anchor=www.adtran.com&in
dex=6&md5=9efa06e02e816ee03a0a93d7e914fa7c

For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com

For investors
Peter Schuman
+1 256 963 6305
investor.relations@adtran.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye